Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Ultragenyx

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Hemophilia B

Treatments: Genetic: DTX101

Study type: Interventional

Funder types: Industry

Identifiers

NCT02618915

101HEMB01

Details and patient eligibility

About

A Phase 1/2, open-label, dose-finding safety study of single ascending doses of DTX101 in adult males with moderate/severe to severe hemophilia B.

Full description

Hemophilia B is an X-linked recessive genetic bleeding disorder caused by mutations in the factor IX (FIX) gene. FIX is produced in the liver and is critical for fibrin clot formation. Hemophilia B is characterized by frequent, spontaneous internal bleeding that can lead to chronic arthropathy (joint damage), intracranial hemorrhage, and even death. In patients with moderate/severe to severe hemophilia B, the majority of bleeding episodes occur in the joints and, if not treated, lead to debilitating damage and a decreased quality of life.

This study will evaluate the safety and efficacy of the adeno-associated virus (AAV) to deliver human factor IX (hFIX) gene, the healthy gene necessary to make FIX, to the liver where FIX is normally produced. This study will determine if AAVrh10 can produce clinically meaningful FIX levels in patients with moderately/severe or severe hemophilia B.

This study was previously posted by Dimension Therapeutics, which has been acquired by Ultragenyx in November 2017.

Enrollment: 6 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male ≥ 18 years of age.
2. Moderate/severe or severe hemophilia B (baseline FIX activity ≤ 2% of normal or documented history of FIX activity ≤2%).
3. At least 3 bleeding episodes per year that require on-demand treatment with FIX OR are treated with a prophylactic regimen of FIX.
4. At least 100 days exposure history to FIX.
5. No documented history of inhibitors (neutralizing antibodies) to exogenous FIX.
6. No known allergic reaction to exogenous FIX or any component of DTX101.
7. Willing to stop prophylactic treatment with recombinant FIX at specified time points during the study.

Exclusion criteria

1. History of significant liver disease (ie, portal hypertension).
2. Significant hepatic inflammation or cirrhosis.
3. Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
4. History of human immunodeficiency virus (HIV) infection AND any of the following: CD4+ cell count < 350 cells/mm^3, change in antiretroviral therapy regimen within 6 months prior to Day 0, or plasma viral load > 200 copies/mL, on 2 separate occasions, as measured by polymerase chain reaction.
5. Anti-AAVrh10 neutralizing antibody titer > 1:5.
6. Participation (current or previous) in another gene therapy study.
7. Participation in another investigational medicine study within 3 months before screening.

NOTE: Other protocol defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 2 patient groups

DTX101, Cohort 1

Experimental group

Description:

a single peripheral intravenous (IV) infusion of 1.6 x 10\^12 genome copies (GC)/kg DTX101

Treatment:

Genetic: DTX101

DTX101, Cohort 2

Experimental group

Description:

a single peripheral IV infusion of 5.0 x 10\^12 GC/kg DTX101

Treatment:

Genetic: DTX101